In October 2024: Novo Nordisk announced plans to invest USD 4.1 billion in expanding US manufacturing capacity for injectable GLP-1 therapies at facilities in North Carolina, addressing ongoing supply constraints for Ozempic and Wegovy that have limited patient access throughout 2023-2024
"The effects of the melanocortin agonist (MT-II) on subcutaneous and visceral adipose tissue in rodents." Peptides
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Scientific studies have shown that GLP-1 receptor agonists like Ozempic can bind to cells and receptors that produce glucagon and signal them to cease production when insulin levels are high
Your compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) whether you are at the starter dose or maintenance dose, with no hidden tier increases
Sold for laboratory use only, it is not an approved drug and has no established human dose